Bivalirudin
Secvenţă:D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
Alias:126:PN:WO2004076484PAG:31 proteine revendicate;Angiomax;BG 8967;Bivalirudin;Hirulog; Hirulog 1
Cas Nr.: 128270-60-0
Formulă moleculară: C98H138N24O33
Greutate moleculară: 2180.29
Puritate (HPLC): 98.0%min.
Aspect: Pudră albă
Impuritate unică (HPLC): 1.0%max
Compoziția aminoacizilor: ±10% din teoretic
Conținutul de peptide (N%): >80.0%
Continut de apa (Karl Fischer): <8.0%
Conținut de trifluoroacetat(HPIC): >12.0%
DOMNIȘOARĂ (ESI): Consistent
Bilanțul de masă: 95.0~105,0%
Nota : Gradul farmaceutic
Depozitare: Închis, de mai jos 2 ~ 8℃ conservare
Utilizare : Acest produs este utilizat în principal pentru prevenirea terapiei intervenționale de formare vasculară în tratamentul anginei instabile., complicatii ischemice inainte si dupa.Inhiba atat trombina circulanta cat si cea legata de cheag, în același timp, inhibă activarea și agregarea trombocitelor mediate de trombină.
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, în același timp, inhibă activarea și agregarea trombocitelor mediate de trombină. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
